Tag: Orphan
Zydus receives USFDA Orphan Drug Designation for Desidustat for the treatment...
Orphan drug designation by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Zydus gets go ahead for phase-2 clinical trial of its novel...
The company will soon begin the Phase II (a) clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Cryopyrin-Associated Periodic Syndrome (CAPS), a rare life-long auto-inflammatory condition in Australia
GNH India clears audit to trade ‘Orphan Drugs’ with UK
With this new development, GNH India becomes one more pharma wholesaler among few to have forayed into the United Kingdom market as a legal distributor of rare and life-saving drugs..........